Beam Therapeutics Stock Performance
| BEAM Stock | USD 28.68 2.11 6.85% |
On a scale of 0 to 100, Beam Therapeutics holds a performance score of 5. The firm shows a Beta (market volatility) of -0.28, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Beam Therapeutics are expected to decrease at a much lower rate. During the bear market, Beam Therapeutics is likely to outperform the market. Please check Beam Therapeutics' semi deviation, sortino ratio, semi variance, as well as the relationship between the standard deviation and value at risk , to make a quick decision on whether Beam Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Beam Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain basic indicators, Beam Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (3.09) | Five Day Return (12.00) | Year To Date Return 20.81 | Ten Year Return 59.15 | All Time Return 59.15 |
1 | Acquisition by Walsh Kathleen E of 16532 shares of Beam Therapeutics at 34.33 subject to Rule 16b-3 | 11/26/2024 |
2 | Insider Trading | 12/02/2024 |
3 | Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference | 01/30/2025 |
4 | FMR LLC Reduces Holdings in Beam Therapeutics Inc | 02/12/2025 |
5 | Wall Street Analysts See a 67.27 percent Upside in Beam Therapeutics Can the Stock Really Move This High | 02/13/2025 |
6 | Moderna Reports Q4 Loss, Tops Revenue Estimates | 02/14/2025 |
7 | CRSP Stock Rises 25 percent in a Week Time to Buy, Hold or Sell | 02/18/2025 |
8 | Apellis Pharmaceuticals, Inc. May Report Negative Earnings Know the Trend Ahead of Next Weeks Release | 02/21/2025 |
| Begin Period Cash Flow | 245.5 M |
Beam |
Beam Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,737 in Beam Therapeutics on November 28, 2024 and sell it today you would earn a total of 342.00 from holding Beam Therapeutics or generate 12.5% return on investment over 90 days. Beam Therapeutics is currently generating 0.2984% in daily expected returns and assumes 4.4237% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Beam, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Beam Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Beam Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Beam Therapeutics, and traders can use it to determine the average amount a Beam Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0675
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BEAM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.42 actual daily | 39 61% of assets are more volatile |
Expected Return
| 0.3 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Beam Therapeutics is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Beam Therapeutics by adding it to a well-diversified portfolio.
Beam Therapeutics Fundamentals Growth
Beam Stock prices reflect investors' perceptions of the future prospects and financial health of Beam Therapeutics, and Beam Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Beam Stock performance.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0928 | ||||
| Profit Margin | (0.41) % | ||||
| Operating Margin | (7.46) % | ||||
| Current Valuation | 1.79 B | ||||
| Shares Outstanding | 82.81 M | ||||
| Price To Earning | 37.48 X | ||||
| Price To Book | 3.22 X | ||||
| Price To Sales | 7.07 X | ||||
| Revenue | 349.64 M | ||||
| Gross Profit | (56.55 M) | ||||
| EBITDA | (415.57 M) | ||||
| Net Income | (132.53 M) | ||||
| Cash And Equivalents | 1.09 B | ||||
| Cash Per Share | 15.90 X | ||||
| Total Debt | 161.43 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 4.64 X | ||||
| Book Value Per Share | 9.97 X | ||||
| Cash Flow From Operations | (149.19 M) | ||||
| Earnings Per Share | (1.58) X | ||||
| Market Capitalization | 2.47 B | ||||
| Total Asset | 1.1 B | ||||
| Retained Earnings | (1.57 B) | ||||
| Working Capital | 1.01 B | ||||
| Current Asset | 2.89 B | ||||
| Current Liabilities | 706.6 M | ||||
About Beam Therapeutics Performance
By examining Beam Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Beam Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Beam Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -12.1 K | -12.7 K | |
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.45) | (0.43) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.51) | (0.54) |
Things to note about Beam Therapeutics performance evaluation
Checking the ongoing alerts about Beam Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Beam Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Beam Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 349.64 M. Net Loss for the year was (132.53 M) with loss before overhead, payroll, taxes, and interest of (56.55 M). | |
| Beam Therapeutics currently holds about 1.09 B in cash with (149.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.9. | |
| Beam Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Apellis Pharmaceuticals, Inc. May Report Negative Earnings Know the Trend Ahead of Next Weeks Release |
- Analyzing Beam Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Beam Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Beam Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Beam Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Beam Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Beam Therapeutics' stock. These opinions can provide insight into Beam Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.58) | Revenue Per Share | Quarterly Revenue Growth (0.17) | Return On Assets | Return On Equity |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.